ISSM Committee Defines Premature Ejaculation
FDA Investigates Testosterone Therapy
The International Society for Sexual Medicine (ISSM) Ad Hoc Committee for the Definition of Premature Ejaculation has agreed on an evidence-based, unified definition that describes both the acquired and lifelong forms of premature ejaculation (PE).
After reviewing scientific literature last spring, the committee unanimously agreed that both lifelong and acquired PE shared certain characteristics, such as short ejaculatory latency, reduced or absent ejaculatory control, and negative personal consequences.
Their unified definition for both conditions states that acquired and lifelong PE is "a male sexual dysfunction characterized by
ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration from the first sexual experiences (lifelong PE), or, a clinically significant and bothersome reduction in latency time, often to about 3 minutes or less (acquired PE), and
the inability to delay ejaculation on all or nearly all vaginal penetrations, and
negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.”
The committee's research will be published soon in the Journal of Sexual Medicine. Please click here for more details.
Meet Your Colleagues: Carolyn Earle of Australia
The U.S. Food and Drug Administration (FDA) has announced plans to investigate the safety of FDA-approved testosterone products in light of heart risks suggested by two studies.
The studies, recently published in the Journal of the American Medical Association (JAMA) and PLOS One, found that men on testosterone therapy were at increased risk for heart attack. In the JAMA study, these men were also at increased risk for stroke and death.
In a safety announcement dated January 31, the FDA wrote, “At this time, FDA has not concluded that FDA-approved testosterone treatment increases the risk of stroke, heart attack, or death. Patients should not stop taking prescribed testosterone products without first discussing any questions or concerns with their health care professionals."
The statement continued, "Health care professionals should consider whether the benefits of FDA-approved testosterone treatment is likely to exceed the potential risks of treatment.”
When the investigation is complete, the FDA will announce its conclusions and recommendations.
To learn more, please click here.
Our latest ISSM Member Profile features Carolyn Earle of western Australia. Ms. Earle is a sexologist in private practice with professional interests in erectile dysfunction. She was involved with the first penile injection in Australia and has been an ISSM member for over thirty years.
When asked about her professional background, Ms. Earle said, "I managed the Keogh Institute for Medical Research for 30 years. During this time, my roles included management of clinical services, sexology case load, and management and procurement of research trials in sexual health."
She says that networking with colleagues and staying updated on the latest clinical research and services are two ways the ISSM benefits her.
Please click here to see Ms. Earle's complete profile.